Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-48P (RNA, U2 small nuclear 48, pseudogene) is a pseudogene in the human genome that is homologous to genes coding for U2 small nuclear RNA (snRNA), a critical component of the spliceosome complex responsible for pre-mRNA splicing in eukaryotic cells. As a pseudogene, RNU2-48P does not produce a functional protein or RNA product and does not play a direct, characterized biological role in humans. Pseudogenes like RNU2-48P typically arise from duplication or retrotransposition events and have lost their original function due to mutations or lack of regulatory elements. The precise NCBI Gene ID for RNU2-48P is 106481649. There are no established alternative names in major databases. As a pseudogene, this locus is not transcribed into a functional U2 snRNA, and there is no evidence it is involved in any active cellular process. Since pseudogenes lack an active biological function, RNU2-48P is not considered a therapeutic target, biomarker, or druggable molecule. The U2 small nuclear RNA family includes active components (U2 snRNAs, e.g., RNU2-1, RNU2-2) essential for spliceosome function, but RNU2-48P itself is non-functional. This gene symbol represents a non-functional, non-protein-coding pseudogene, making it an incorrect or uninformative entry for therapeutic target lists. In summary, RNU2-48P is a pseudogene and is not a biologically active target or relevant for therapeutic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 48, pseudogene (RNU2-48P).